What does a payer want to see before approving dulaglutide?

The pharmacy is accredited and I have verified that on the accreditor register.

This is a procedural question rather than a theoretical one, and I would like the procedure rather than the theory.

What I have done so far is read the label documentation where it exists and the two pharmacopoeial monographs that are publicly available, which cover the licensed presentation and say nothing about a research one.

What would you do, and what would you check afterwards?

The salt-versus-base issue is worth understanding precisely because it is a genuine regulatory tell rather than a technicality.

Whether a telehealth prescription can be filled at a retail pharmacy depends on the prescription and the jurisdiction rather than on the modality: a prescription for a licensed product from a prescriber licensed in the patient’s jurisdiction is generally fillable anywhere that stocks it. A prescription written to a specific compounding pharmacy for a preparation only that pharmacy makes is not portable, and that non-portability is sometimes the commercial point.

A beyond-use date for a compounded multi-dose preparation is set under USP chapter provisions on the basis of microbiological risk category and, where available, supporting stability data. In practice most beyond-use dates in this space are default values from the risk-category table rather than the output of a stability study, and the two should not be read as equivalent claims.

FDA drug shortage list status is published and is the operative fact for whether compounding a copy of an approved drug is permitted under the relevant statutory exemptions; the status changes, and the change has downstream consequences for supply.

If the intake did not ask about contraindications, that tells you what kind of service it is.

edited 12 Mar 2025 by meniscus_film — clarified the distinction between purity and content

Prior authorisation is an adjudication against written criteria, and the criteria are usually obtainable. Requesting them before submitting is the single highest-yield step in the process.

The salt-form point: the statutory pathway for compounding a copy of an approved drug during a shortage applies to the same active moiety as the approved product. A preparation described as a salt form — "semaglutide sodium", "semaglutide acetate" — is describing a different chemical entity from the approved base, and the description is usually there to construct an argument that it is not a copy. Whatever the legal merits, it means what is in the vial is not what was studied.

Specifically, twelve-month cost modelling, laid out: take the monthly product cost, add consultation or subscription fees, add laboratory monitoring at your chosen interval, add shipping, and then adjust the product cost for actual delivered content and dead-space loss. The route that looks cheapest per vial frequently is not cheapest per twelve months, because the fee structure and the monitoring dominate at lower product costs.

I would flag that a compounded preparation and an approved product are different objects even when they nominally contain the same molecule, and the difference is release testing rather than intent.

Verify accreditation on the accreditor’s register rather than on the pharmacy’s website. It takes a minute.

The distinction that governs most of this is between a preparation made for an identified patient against a prescription and a preparation made in bulk for office stock, and the two sit under different statutory provisions with different testing obligations.

503A and 503B differ in what they are permitted to do and what they must demonstrate. A 503A pharmacy compounds against individual prescriptions, is exempt from current good manufacturing practice requirements, and is regulated primarily at state level with USP chapter compliance as the operative standard. A 503B outsourcing facility registers federally, must comply with cGMP, may prepare without patient-specific prescriptions, and is subject to FDA inspection. The practical consequence is that a 503B preparation carries release testing and a 503A preparation generally does not.

Accreditation by the Pharmacy Compounding Accreditation Board or by ACHC is voluntary and verifiable, and verification is a matter of checking the accreditor’s register rather than accepting a logo on a website.

The caveat is jurisdictional. Almost everything in this area is specific to a country and often to a sub-national jurisdiction, and a confident answer that does not name a jurisdiction should be treated as describing somewhere else.

Ask for the written criteria before you submit. Everything else in the process is easier once you have them.

Model the cost across the whole route, including the parts that are not the drug: consultation fees, laboratory monitoring, shipping, and the tests you will pay for yourself.

Features of a defensible telehealth intake: a real history including contraindications and family history, a recorded weight and height rather than a self-attested figure, baseline laboratory work or a documented reason for its absence, a named prescriber you can identify and verify, a titration plan, and a mechanism for reporting adverse events that reaches a clinician. A checkbox intake that issues a prescription in four minutes has none of these.

The statutory basis for the 503A/503B distinction is sections 503A and 503B of the US Federal Food, Drug, and Cosmetic Act as amended by the Drug Quality and Security Act of 2013, and the FDA’s guidance documents on each are the authoritative description of what is permitted.

The limitation of cost modelling is that it assumes a stable price environment, and the price environment in this category has been anything but stable.

Model twelve months, not one. The fee structures are designed to be compared monthly.